Global Cell Based Cartilage Repair/Regeneration Market Size Likely to Reach at a CAGR of 5.3% By 2033

As per the current market research conducted by CMI Team, the global Cell Based Cartilage Repair/Regeneration Market size is expected to record a CAGR of 5.3% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 675.4 million. By 2032, the valuation is anticipated to reach USD 981.7 million.

Cell Based Cartilage Repair/Regeneration Market: Growth Factors and Dynamics

• Growing Aging Population: The global aging population has contributed to the escalating cases of cartilage-related disorders. As people age, the natural regenerative capacity of cartilage diminishes, making elderly individuals more susceptible to cartilage injuries and degeneration. This demographic trend has created a substantial market for cell-based cartilage repair solutions.

• Increasing Awareness and Acceptance: Growing awareness among patients and healthcare professionals about the potential benefits of cell-based therapies for cartilage repair has positively influenced market growth. Additionally, a rising number of successful case studies and clinical trials have improved the acceptance and adoption of these treatments.

• Advantages over Traditional Treatments: Cell-based cartilage repair/regeneration therapies offer several advantages over traditional treatments like pain management and invasive surgeries. The potential for tissue regeneration and reduced need for repeated interventions make them an attractive option for both patients and healthcare providers, contributing to market growth.

• Growing Investment and Research Funding: The cell-based cartilage repair/regeneration market has witnessed a surge in investment from pharmaceutical companies, venture capitalists, and government organizations. This increased funding has accelerated research and development efforts, leading to the introduction of more innovative and effective cell-based therapies.

• Rising Healthcare Expenditure and Insurance Coverage: The increasing healthcare expenditure and improved insurance coverage for regenerative therapies have positively impacted the cell-based cartilage repair/regeneration market. As more patients can access these advanced treatments, the demand for cell-based therapies is expected to grow further.

• Patient Preference for Personalized Medicine: As patients become more informed about medical advancements, there is a growing preference for personalized medicine. Cell-based cartilage repair/regeneration therapies offer the potential for personalized treatment plans tailored to individual patients, considering their specific cartilage defects and medical history. This patient-centric approach further drives the adoption of cell-based therapies in the market.

Cell Based Cartilage Repair/Regeneration Market: Partnership and Acquisitions

• Vericel Corporation and Medivir AB (2018): Vericel Corporation, a leader in regenerative medicine, partnered with Medivir AB to develop and commercialize a novel cell-based therapy for cartilage repair. This collaboration aimed to leverage Medivir’s expertise in antiviral research and Vericel’s proficiency in cell-based therapies to accelerate the development of innovative cartilage regeneration treatments.

• Medtronic’s Acquisition of Medicrea International (2021): Medtronic, a leading medical device company, acquired Medicrea International, a company specializing in personalized spine surgery and orthopaedic implants. Although this acquisition was primarily focused on the spine market, it also provided Medtronic with opportunities to explore and expand its presence in the broader regenerative medicine field, including cartilage repair.

Report Scope

Cell Based Cartilage Repair/Regeneration Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Cell based Cartilage Repair/Regeneration Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Research and Clinical Trials: The COVID-19 pandemic led to disruptions in research activities and clinical trials related to cell-based cartilage repair/regeneration. Many research institutions and companies had to suspend or delay their studies, leading to setbacks in the development of new therapies and treatments.

• Reduced Access to Healthcare Facilities: During the height of the pandemic, access to healthcare facilities was limited, and elective procedures were often postponed. As a result, patients seeking cell-based cartilage repair treatments faced challenges in accessing these therapies, affecting the demand and revenue for such treatments.

• Resumed Research and Clinical Trials: As the situation improves and restrictions ease, research activities and clinical trials related to cell-based cartilage repair/regeneration are likely to resume. This will accelerate the development of new treatments and technologies in the market.

• Emphasis on Minimally Invasive Treatments: The focus on infection prevention and patient safety during the pandemic has led to a preference for minimally invasive treatments. Cell-based cartilage repair/regeneration therapies, being less invasive compared to traditional surgeries, are expected to gain traction as a safer treatment option in the post-COVID era.

• Government Support and Funding: Governments worldwide are likely to continue supporting regenerative medicine research and development in the aftermath of the pandemic. Funding initiatives and policy support can stimulate growth in the cell-based cartilage repair/regeneration market and encourage more investments in the sector.

• Integration of Digital Health Solutions: As the healthcare industry adapts to the challenges posed by the pandemic, there is increasing integration of digital health solutions in patient care. These solutions, such as remote monitoring devices and wearable technology, can assist in tracking patients’ progress after post-cell-based cartilage repair/regeneration treatments. The integration of digital health tools not only enhances patient outcomes but also provides valuable data for further research and improvement of cell-based therapies.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Cell based Cartilage Repair/Regeneration Market, with some challenges and opportunities arising from the pandemic. Manufacturers and retailers need to remain agile and adapt to the changing market conditions to overcome these challenges and capitalize on new growth opportunities.

List of the prominent players in the Cell Based Cartilage Repair/Regeneration Market:

• Vericel Corporation
• Osiris Therapeutics Inc. (now part of Smith & Nephew)
• Zimmer Biomet Holdings Inc.
• Anika Therapeutics Inc.
• BioTissue AG (now part of Smith & Nephew)
• Histogenics Corporation (acquired by Ocugen Inc.)
• RTI Surgical Holdings Inc.
• Arthrex Inc.
• CollPlant Biotechnologies Ltd.
• CellGenix GmbH
• Others

The Cell Based Cartilage Repair/Regeneration Market is segmented as follows:

By Therapy Type

• Autologous Cell Therapy
• Allogeneic Cell Therapy
• Others

By Mode of Administration

• Intra-articular Injection
• Scaffold Implantation
• Surgical Implantation

By End Users

• Hospitals and Clinics
• Research Institutions and Biotechnology
• Pharmaceutical Companies

By Region

North America

• The U.S.
• Canada
• Mexico

Europe

• France
• The UK
• Spain
• Germany
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America